Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $24.43 Consensus Price Target from Analysts

by · The Cerbat Gem

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $24.4286.

Several analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Piper Sandler upped their price objective on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, November 24th.

Check Out Our Latest Report on DAWN

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $8.85 on Friday. The firm has a market capitalization of $908.72 million, a PE ratio of -5.82 and a beta of -1.27. The business has a 50 day simple moving average of $8.77 and a two-hundred day simple moving average of $7.59. Day One Biopharmaceuticals has a 1 year low of $5.64 and a 1 year high of $13.53.

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The firm had revenue of $39.80 million during the quarter, compared to analyst estimates of $38.20 million. During the same period in the previous year, the firm earned $0.38 earnings per share. The business’s revenue was down 57.6% on a year-over-year basis. Equities research analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Adam Dubow sold 4,319 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $8.91, for a total transaction of $38,482.29. Following the completion of the transaction, the insider owned 62,626 shares in the company, valued at approximately $557,997.66. The trade was a 6.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jeremy Bender sold 15,894 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $8.91, for a total value of $141,615.54. Following the transaction, the chief executive officer directly owned 177,165 shares of the company’s stock, valued at $1,578,540.15. The trade was a 8.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 28,001 shares of company stock valued at $249,489. 6.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Rubric Capital Management LP acquired a new stake in Day One Biopharmaceuticals in the 3rd quarter valued at $23,808,000. Alyeska Investment Group L.P. boosted its holdings in shares of Day One Biopharmaceuticals by 61.6% during the first quarter. Alyeska Investment Group L.P. now owns 4,059,764 shares of the company’s stock valued at $32,194,000 after acquiring an additional 1,547,577 shares during the period. AIGH Capital Management LLC bought a new stake in shares of Day One Biopharmaceuticals during the third quarter valued at approximately $10,719,000. Mak Capital One LLC bought a new position in shares of Day One Biopharmaceuticals in the third quarter worth $10,212,000. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth about $9,758,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

(Get Free Report)

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.

Read More